RecruitingPhase 3

Darbepoetin in Patients Candidates for Liver Transplant. (EPO-LT Trial)

Spain140 participantsStarted 2025-11-25

Plain-language summary

This is a national multicenter, randomized clinical trial to evaluate the the efficacy and safety of DP administration in patients on the liver transplant waiting list to reduce intraoperative red blood cell concentrate transfusion.

Who can participate

Age range18 Years – 70 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Age ≥ 18 years old
✓. Patients on the official liver transplant waiting list
✓. Hemoglobin (Hb) level ≤ 11.5 g/dL
✓. Women of child-bearing potential\* must have a negative pregnancy test in serum before the inclusion in the study and agree to use highly effective contraceptive methods during the study. Highly effective contraceptive methods will include: intrauterine device, bilateral tubal occlusion, vasectomized partner and sexual abstinence\*\* (only if refraining from heterosexual intercourse during the period of twelve months). Hormonal contraceptive methods will be avoided due to the risk of adverse events and impairment of liver function.

What they're measuring

to investigate the efficacy and safety of darbepoetin (DP) administration in patients on the liver transplant (LT) waiting list to reduce intraoperative red blood cell concentrate transfusion.

Timeframe: perioperative

Trial details

NCT IDNCT07169643

SponsorFundacion Clinic per a la Recerca Biomédica

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-12

Contact for this trial

Anna cruceta, Dr

+93 2275400 acruceta@recerca.clinic.cat

View on ClinicalTrials.gov More Liver Transplant; Complications trials